---
schema_version: "secwatch.filing_event.v1"
accession: "0001129928-26-000035"
form_type: "8-K"
ticker: "ONCY"
cik: "0001129928"
company_name: "ONCOLYTICS BIOTECH INC"
filed_at: "2026-05-22T13:03:22+00:00"
generated_at: "2026-05-22T13:04:40.096530+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Oncolytics posts translational data from GOBLET/AWARE-1 at ASCO 2026 supporting pelareorep immune activation

## Summary
- Data from GOBLET (advanced pancreatic cancer) and AWARE-1 (early-stage breast cancer) to be presented at ASCO 2026 May 29-June 2.
- In pancreatic cancer, expansion of pre-existing TIL clones correlated with tumor volume reduction; mutant KRAS-specific T-cell clones expanded.
- In breast cancer, increased antiviral/immune gene expression, CXCL13 induction, and tertiary lymphoid structure formation by imaging mass cytometry.
- Abstract 'Influence of pelareorep on mutant KRAS-specific blood TIL clonal expansion' (No. 2664) presented May 30, 1:30-4:30 p.m. CT.

## SEC filing metadata
- accession: 0001129928-26-000035
- form_type: 8-K
- ticker: ONCY
- cik: 0001129928
- company_name: ONCOLYTICS BIOTECH INC
- filed_at: 2026-05-22T13:03:22+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/0001129928-26-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1129928/000112992826000035/oncy-20260522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001129928-26-000035
- JSON: https://secwatch.observer/filing/0001129928-26-000035.json
- Plain text: https://secwatch.observer/filing/0001129928-26-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.